Thanks for sharing this. I am a little confused as to why the...

Thanks for sharing this. 

I am a little confused as to why the DSMB is expected in a month or two, which is after all patients complete treatment. Doesn't that defeat the purpose? Perhaps they want to show the market there is absolutely no concern for safety by not releasing it until after this treatment completion date (Feb 26)?

In the unlikely event that both prodromal and at risk markets are successfully penetrated, yearly revenue could be around the $20 billion mark based on the 15% royalties from your previous post on the other thread. And based on your conservative PE ratio of 15, the SP looks something more like $300. I'm not naive enough to think that this could or ever will eventuate. But it is interesting how high the numbers go when calculating rational figures.

Is it May yet?